Nicholas Gravbrot

Mr. Nicholas Gravbrot

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2019 in Antibodies
Verified
Journal Article
Open access
PDF file
NGNicholas Gravbrot
Nicholas Gravbrot
KGKacy Gilbert-Gard
Kacy Gilbert-Gard
PMParas Mehta
Paras Mehta
YGYarah Ghotmi
Yarah Ghotmi
MBMadhulika Banerjee
Madhulika Banerjee
SSSrinath Sundararajan
Srinath Sundararajan
Recently, modulation of immune checkpoints has risen to prominence as a means to treat a number of solid malignancies, given the durable response seen in many patients and improved side effect profile compared to conventional chemotherapeutic agents. Several classes of immune checkpoint modulators have been developed. Here, we review current monoclonal antibodies directed against immune checkpoints that are employed in practice today. We discuss the history, mechanism, indications, and clinical data for each class of therapies. Furthermore, we review the challenges to durable tumor responses that are seen in some patients and discuss possible interventions to circumvent these barriers.

13 May 2020 in Stereotactic and Functional Neurosurgery
Verified
Journal Article
Closed access
NGNicholas Gravbrot
Nicholas Gravbrot
MSManojkumar Saranathan
Manojkumar Saranathan
NPNader Pouratian
Nader Pouratian
WKWillard Kasoff
Willard Kasoff
Direct targeting methods for stereotactic neurosurgery in the treatment of essential tremor have been the subject of active research over the past decade but have not yet been systematically reviewed. We present a clinically oriented topic review based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses Group guidelines. Our focus is studies using advanced magnetic resonance imaging (MRI) techniques (ultrahigh-field structural MRI, diffusion-weighted imaging, diffusion-tensor tractography, and functional MRI) for patient specific, in vivo identification of the ventral intermediate nucleus and the dentato-rubro-thalamic tract.

10 February 2024 in European Journal of Cancer
Verified
Journal Article
Closed access
NGNicholas Gravbrot
Nicholas Gravbrot
CWChristopher R. Weil
Christopher R. Weil
CDCristina M. DeCesaris
Cristina M. DeCesaris
DGDavid K. Gaffney
David K. Gaffney
GSGita Suneja
Gita Suneja
LBLindsay M. Burt
Lindsay M. Burt

17 May 2019 in Journal of Neurological Surgery Part B: Skull Base
Verified
Journal Article
Closed access
PDF file
NGNicholas Gravbrot
Nicholas Gravbrot
HJHeidi Jahnke
Heidi Jahnke
WWWilliam L. White
William L. White
ALAndrew S. Little
Andrew S. Little
Objectives Transsphenoidal surgery creates a skull base defect that may cause postoperative cerebrospinal fluid (CSF) leakage or pneumocephalus. This study reviewed the institutional experience of a pituitary center in managing patients who use positive-pressure ventilation (PPV) devices for obstructive sleep apnea (OSA) after transsphenoidal surgery, which risks disturbing the skull base repair. Design Retrospective review. Setting Pituitary referral center in a major metropolitan medical center. Methods PPV was resumed at the discretion of the treatment team based on intraoperative findings and OSA severity. Perioperative complications related to resuming and withholding PPV were recorded. Participants Transsphenoidal surgery patients with OSA using PPV devices. Main Outcome Measures Intracranial complications before and after resuming PPV. Results A total of 42 patients met the study criteria. Intraoperative CSF leakage was encountered and repaired in 20 (48%) patients. Overall, 38 patients resumed PPV (median: 3.5 weeks postsurgery; range: 0.14–52 weeks) and 4 patients did not resume PPV. Postoperatively, no patient experienced CSF leakage or pneumocephalus before or after resuming PPV. Four (10%) patients required temporary nocturnal supplemental oxygen at home, one patient was reintubated after a myocardial infarction, and one patient had a prolonged hospital stay due to chronic obstructive pulmonary disease exacerbation. Conclusions Resuming PPV use after transsphenoidal surgery did not result in intracranial complications. However, delay in resuming PPV resulted in four patients requiring oxygen at home. We propose a preliminary PPV device management algorithm based on the size of the intraoperative CSF leak to facilitate future studies.

14 April 2020 in Movement Disorders Clinical Practice
Verified
Journal Article
Closed access
PDF file
NGNicholas Gravbrot
Nicholas Gravbrot
ABAaron Burket
Aaron Burket
MSManojkumar Saranathan
Manojkumar Saranathan
WKWillard Kasoff
Willard Kasoff

4 August 2017 in Neurosurgery
Verified
Journal Article
Closed access
PDF file
NGNicholas Gravbrot
Nicholas Gravbrot
DKDaniel F Kelly
Daniel F Kelly
JMJohn Milligan
John Milligan
CGChester F Griffiths
Chester F Griffiths
GBGarni Barkhoudarian
Garni Barkhoudarian
ALAndrew S Little
Andrew S Little
The minimal clinically important difference (MCID) is defined as the smallest change in health-related quality of life (QOL) that patients consider meaningful. The MCID is essential for determining clinically significant changes, rather than simply statistically significant changes, in QOL scores. The Anterior Skull Base Nasal Inventory-12 (ASK Nasal-12), a site-specific sinonasal QOL instrument, has emerged as a standard instrument for assessing QOL in patients who have undergone endonasal transsphenoidal surgery. To determine the MCID for the ASK Nasal-12. Distribution- and anchor-based methods were used to determine the MCID for the ASK Nasal-12 based on raw data from a multicenter prospective QOL study of 218 patients. Two distribution-based statistical methods, the one-half standard deviation method and the effect-size method, both yielded MCIDs of 0.37 (medium effect). The first anchor-based method, using the 2-wk postoperative overall nasal functioning item as the anchor, yielded an MCID of 0.31. The second anchor-based method, using the 2-wk postoperative Short Form Health Survey 8 bodily pain item as the anchor, yielded an MCID of 0.29. The largest MCID obtained for the ASK Nasal-12 using 4 statistical methods 2 wk postoperatively was 0.37. This information provides clinicians with an essential context for determining the clinical significance of changes in QOL scores after interventions. Our results will help clinicians better interpret QOL scores and design future studies that are powered to detect meaningful QOL changes.